Market Access Europe Flow Neuroscience holds a unique position as Europe and UK’s only medically approved brain stimulation headset and home therapy app for MDD, presenting a clear entry path to hospitals, clinics, and digital health networks for at home treatment adoption across Europe and the UK.

Clinical Trials With clinical trial partnerships such as Curebase and Pharma Vends and ongoing investor backing, there is an opportunity to partner with pharma and contract research organizations to generate clinical evidence, recruit patients, and expand indications for Flow’s at home headset.

Strategic Partnerships Flow has attracted notable investors and collaborators, indicating credibility for strategic alliances with distributors, healthcare providers, and payers to scale adoption. Explore regional distributors and health system partnerships to reach target markets more efficiently.

Telehealth Integration Flow combines a medical device with a therapy app, aligning well with telemedicine and digital health ecosystems. Propose joint integrations with telehealth platforms and clinics to enable remote prescription, monitoring, and outcomes tracking for MDD treatment.

Payer Adoption To accelerate adoption, focus on building robust outcomes data and cost effectiveness analyses to engage payers and healthcare systems, leveraging brand credibility from a brand refresh and regulatory status to secure coverage and reimbursement and enable broader patient access.